These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25673032)

  • 41. Histopathology of lung adenocarcinoma based on new IASLC/ATS/ERS classification: prognostic stratification with functional and metabolic imaging biomarkers.
    Lee HY; Jeong JY; Lee KS; Yi CA; Kim BT; Kang H; Kwon OJ; Shim YM; Han J
    J Magn Reson Imaging; 2013 Oct; 38(4):905-13. PubMed ID: 23908132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
    Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
    J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
    Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
    J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biopsy findings in PET/CT-positive lung lesions in a community hospital.
    Lobrano MB; Hayman E; Dekelbaum M; Campeau R
    J La State Med Soc; 2005; 157(6):319-24. PubMed ID: 16579344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT.
    Chun EJ; Lee HJ; Kang WJ; Kim KG; Goo JM; Park CM; Lee CH
    Lung Cancer; 2009 Aug; 65(2):180-6. PubMed ID: 19155090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combining transbronchial biopsy using endobronchial ultrasonography with a guide sheath and positron emission tomography for the diagnosis of small peripheral pulmonary lesions.
    Mizugaki H; Shinagawa N; Kanegae K; Yamada N; Asahina H; Kikuchi E; Oizumi S; Tamaki N; Nishimura M
    Lung Cancer; 2010 May; 68(2):211-5. PubMed ID: 19595471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.
    Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S
    Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5.
    Chen CJ; Lee BF; Yao WJ; Cheng L; Wu PS; Chu CL; Chiu NT
    AJR Am J Roentgenol; 2008 Aug; 191(2):475-9. PubMed ID: 18647920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging.
    Stolzmann P; Veit-Haibach P; Chuck N; Rossi C; Frauenfelder T; Alkadhi H; von Schulthess G; Boss A
    Invest Radiol; 2013 May; 48(5):241-6. PubMed ID: 23070096
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies.
    Grueneisen J; Schaarschmidt BM; Beiderwellen K; Schulze-Hagen A; Heubner M; Kinner S; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L
    J Nucl Med; 2014 Dec; 55(12):1930-5. PubMed ID: 25453042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
    Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
    Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT.
    Satoh Y; Ichikawa T; Motosugi U; Kimura K; Sou H; Sano K; Araki T
    AJR Am J Roentgenol; 2011 Feb; 196(2):447-53. PubMed ID: 21257899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
    Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
    Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recurrence and metastasis of lung cancer demonstrate decreased diffusion on diffusion-weighted magnetic resonance imaging.
    Usuda K; Sagawa M; Motomo N; Ueno M; Tanaka M; Machida Y; Maeda S; Matoba M; Tonami H; Ueda Y; Sakuma T
    Asian Pac J Cancer Prev; 2014; 15(16):6843-8. PubMed ID: 25169535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18-fluorine fluorodeoxyglucose positron emission tomography with computerized tomography versus computerized tomography alone for the management of solitary lung nodules with diameters inferior to 1.5 cm.
    Divisi D; Di Tommaso S; Di Leonardo G; Brianzoni E; De Vico A; Crisci R
    Thorac Cardiovasc Surg; 2010 Oct; 58(7):422-6. PubMed ID: 20922626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
    Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
    Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.